Charting Patient-specific Regulators of Plasticity in Primary and Metastatic Colorectal Cancer

MRC · United Kingdom government procurement

GlobalGov surfaces government procurement from around the world, including the markets your competitors overlook.

June 30, 2029
Response Due
Active
Status

Opportunity Overview

Bowel cancer afflicts >900,000 people worldwide and is a major source of cancer-related mortality. While surgical resection of primary bowel tumours is occasionally curative, metastases in other organs such as the liver are responsible for residual disease and ultimately patient death. Existing bowel cancer chemotherapies target fast-growing cancer cells while sparing slow-growing cells. Unfortunately, new research has revealed that bowel cancer cells can rapidly change from fast-growing into slow-growing cells to escape chemotherapy. Such cellular 'plasticity' is now considered to be a fundamental feature of bowel cancer. Unfortunately we currently have no way to target plasticity to treat either primary or metastatic bowel cancer.
This MRC Research Grant will explore the inter- and intra-cellular signalling mechanisms controlling cellular plasticity in both primary and metastatic bowel cancer. Using a combination of patient-derived mini-tumour models (known as organoids) from primary and metastatic bowel cancer, novel high-throughput single-cell analysis technologies, and advanced computational methods, we will chart the cell-extrinsic and cell-intrinsic processes that regulate bowel cancer plasticity. Specifically, we will address the following research questions:

Question 1: What are the cell-extrinsic cues that regulate cellular plasticity and drug responses in primary and metastatic CRC and how do these vary across patients?
Question 2: How do cell-extrinsic cues signal via post-translational modifications (PTMs) to regulate gene expression programmes required for plasticity?
Question 3: How can we control patient-specific stem cell plasticity to improve therapeutic responses?

We will investigate these questions by integrating three novel technology platforms:
1) A cohort of x20 primary and x20 metastatic CRC patient-derived organoids (PDOs) from Memorial Sloan Kettering Cancer Centre (MSKCC) (Moorman et al., Nature, in press) and University College...

This is one of 1,831 active United Kingdom Research Development opportunities most of your competitors will never see.

Your competitors are watching the same crowded contracts everyone else is. Track this opportunity and every one like it worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.

Start Free

Solicitation Details

Issuing agencyMRC
CountryUnited Kingdom
CategoryResearch Development
PublishedJune 30, 2025
Procurement stageActive solicitation
Response dueJune 30, 2029
StatusOpen — accepting responses
Official sourceView original notice
Last verifiedAugust 12, 2026

Source: UK Research and Innovation (UKRI) — Open Government Licence v3.0.

Related Opportunities in United Kingdom

Rotation year
Title of project: Evaluation of the quantitative accuracy and radiation dosimetry of an advanced pre-clinical multipinhole SPECT/CT theranostic imag
Discerning MCT1s role in chromatin remodelling and metabolomics changes in cancer progression
Leveraging real world data to characterise the long term impact of COVID-19
Bacterial antibiotic resistance: structure, mechanism and inhibition of ABC transporters responsible for drug efflux and cell wall biogenesis.
Characterising the role of TEX12 in centrosome and cilia development
Allogeneic Chondroprogenitor Therapy (Phase II) (ACT2)
Iron and immunity

See every United Kingdom Research Development opportunity your competition is missing. Free for 14 days.

Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.

Start Free Trial — No Card Required

Free 14-day trial · no card required

See who is already competing here →

Get a free United Kingdom Research Development intelligence report in your inbox

A personalized report on United Kingdom Research Development opportunities, emailed in 5-10 minutes. One per month, no account needed.